Every year, an alarming number of babies are born prematurely across the globe, encountering a host of health issues and ...
Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...